A version of this story also appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

WASHINGTON — Florida may very well be the first state in the nation to successfully import drugs from Canada, but it’s going to be some time before the pills start flowing to the Sunshine State.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • What is often missed in media coverage of drug importation is that the law, which permits importation of lower-cost drugs, applies a different standard to personal importation (people buying medicine directly from pharmacies in other countries). 21 U.S.C. 384 states that the Secretary (Health and Human Services) “SHOULD exercise discretion to permit individuals to make such importations in circumstances in which (i) the importation is clearly for personal use; and (ii) the prescription drug or device imported does not appear to present an unreasonable risk to the individual.” [CAPS emphasis added].

    In contrast, Florida, as this article points out, must demonstrate “no additional risk” will occur from its importation plan to get the green light from HHS. It’s much easier to show that a personal import of a medication from a licensed pharmacy in another country does not “present and unreasonable risk to the individual.” With Americans looking for lower drug prices from Canada and other countries (See https://www.statnews.com/pharmalot/2019/08/14/canada-importation-drug-prices/): is HHS/FDA doing what Congress says it “should” do right now? Could they be making it easier and safer for Americans who choose to import medicine for personal use because they can’t afford it here?

  • To amplify my comment above: The Florida paper misrepresents the requirements of the DSCSA. In particular, it ignores the requirement that drug makers and repackagers add DSCSA-specified product identifiers to their packages. These identifiers must include a unique standardized numerical identifier on each package and case, per section 582(b)(2) of the DSCSA. The so-called safety measures outlined in the report are nothing more than window dressing to hide the missing elements of DSCSA compliance. See my STAT op-ed with Dirk Rodgers: https://drugch.nl/2JsYogg

    Proponents of importation seem to believe that HHS/FDA can magically alter the law through regulation. I’m not a lawyer, but I don’t think it works that way.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy